S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

IPO Filing: NovaBay Pharmaceuticals

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

NovaBay Pharmaceuticals has filed to come public via an IPO, although this one is being put on the American Stock Exchange instead of NASDAQ or NYSE.  It will also trade in Canada on the Toronto Stock Exchange, and its ticker will be NBY.  Terms have not been set in the offering, but it lists up to $23 million as the amount to be raised for filing purposes.  Dundee Securities is the sole underwriter.

NovaBay has developed a class of antimicrobial compounds (Aganocide compounds) that may form a platform to create products that address the treatment and prevention of bacterial infections in hospital and non-hospital settings.  They also have a collaboration and licensing agreement with an affiliate of Alcon, Inc. (ACL-NYSE) to develop products incorporating Aganocide compounds for use in the eye, ear and sinus, as well as in contact lens solutions.  Its major push and key development efforts are focused on Aganocide compounds NVC-422 to treat patients with infections of the eye, ear and sinus, to create an improved environment for the healing of wounds and to prevent infections that result from surgical or other hospital procedures, or that can be caused by the use of products which can introduce an infection into the body.

For all practical purposes this is a pre-revenue stage company.

Jon C. Ogg
February 15, 2007

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Douglas A. McIntyre |

IPO FILING: Acclarent

A company called Acclarent, Inc. has filed to come public via an IPO of up to $86.25 million in common…
Douglas A. McIntyre |

NYSE Amendment To Allow For SPAC IPO’s (NYX, NDAQ)

The NYSE Euronext (NYSE: NYX) has made proposed rule changes this week that would allow the listing of Acquisition Companies…
Motif Bio Closes in on IPO
Chris Lange |

Motif Bio Closes in on IPO

Motif Bio has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Chris Lange |

PharMEDium Files for IPO

PharMEDium Healthcare Holdings has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Jon C. Ogg |

Intrexon IPO Filing: Better DNA for Health Care, Food, Energy, Environment

ThinkstockIntrexon Corp. has filed its paperwork with the Securities and Exchange Commission to allow the company to come public in…
Chris Lange |

Ooma Prices Initial Public Offering

ThinkstockOoma, Inc. filed an amended Form S-1 with the U.S. Securities and Exchange Commission (SEC) to price its initial public offering…
Chris Lange |

Penumbra Sets Terms for IPO in New Filing

Penumbra Inc. has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
VICI Properties Gears Up for IPO
Chris Lange |

VICI Properties Gears Up for IPO

Hospitality and entertainment real estate holder VICI Properties has amended its filing with the SEC regarding its initial public offering.
Visterra Gears Up for IPO
Chris Lange |

Visterra Gears Up for IPO

Visterra has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618